Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension trial of enlicitide in adults with hypercholesterolemia after prior MK-0616 studies
NL-OMON59964Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Aug 2024
- Modality
- Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of enlicitide in hypercholesterolemia, sponsored by Merck & Co. Primary endpoints: Number of participants with one or more adverse events and Number of participants who discontinue study drug due to an adverse event. Started Aug 2024; status: active, not recruiting.
02
Drugs
enlicitide
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NL-OMON59964.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59964.